上海交大赵大海关于新冠疫情第53次在电视台访谈评论:中国加入新冠疫苗实施计划是践行人类健康命运共同体的标志

上海交通大学国际与公共事务学院博士生导师、上海交通大学-耶鲁大学卫生政策联合研究中心执行主任赵大海,自新冠肺炎疫情暴发以来,对于新冠疫情暴发、防控以及医疗卫生体制改革第33次在中央电视台进行直播访谈评论,也是第53次在央视、上视进行访谈评论。在2020年10月11日,赵大海在中央电视台英语频道的《中国24小时》节目,就中国加入新冠肺炎疫苗实施计划(COVAX)的意义以及中国承诺将新冠疫苗作为全球公共产品对全球疫情抗击的重要性等话题进行了直播访谈评论。现将访谈内容翻译并摘录如下。

主持人:从您的角度来看,中国参与新冠肺炎疫苗实施计划(COVAX)对全球抗击新冠疫情意味着什么?

赵大海:中国加入新冠肺炎疫苗实施计划对这个项目具有重要的意义。首先,在中国加入之前,虽然该项目已包括了一百七十多个国家或地区,但没有一个国家或地区拥有已进入第三期临床试验的新冠疫苗。也就是说,在中国加入之前,新冠肺炎疫苗实施计划(COVAX)类似于一个乌托邦项目。由于中国已有四种处于临床三期的新冠疫苗,中国的加入就使得该项目的存在正式具有现实意义。其次,对于全球抗击新冠疫情而言,鉴于新冠肺炎疫苗实施计划各国或地区均目前尚不具备研发和生产新冠疫苗的能力,中国加入该项目在很大程度上意味着全球共同抗击新冠疫情的开始。此外,由于中国新冠疫情在近半年以来已得到了控制,而且中国拥有世界上9种临床三期新冠疫苗中的4种,因此,中国加入该计划的目的是为了帮助全世界,特别是发展中国家共同抗击新冠大流行。

主持人:中国承诺将其新冠疫苗作为全球公共产品,确保发展中国家拥有平等获得的权利。鉴于我们可以期待的全球共同抗击新冠疫情,新冠疫苗作为全球公共产品的重要性是什么?

赵大海:中国承诺新冠疫苗为全球公共产品的最重要意义是这是践行人类健康命运共同体的开端。全球目前只有四个国家的新冠疫苗处于临床三期。除中国外,其他三个国家分别是美国、英国和俄罗斯。对于绝大多数发展中国家而言,他们确实很难有能力来研发出新冠疫苗。如果这三个处于新冠疫苗临床三期的国家,也同中国一样做出相同的承诺,即将新冠疫苗作为全球公共产品,不仅有利于在全球范围内尽快战胜新冠疫情,也有利于世界各国达成为防范未来全球大流行建立起共同的防控机制。唯有如此,人类才有机会避免下一次大流行的到来。

供稿者:国务学院

日期:2020年10月12日


Dahai ZHAO’s 53th comments on TV during the pandemic: China’s joining COVAX is the outset of a shared community of health for all

Dahai Zhao, a doctoral supervisor at the School of International and Public Affairs of Shanghai Jiao Tong University and Executive Director of Shanghai Jiao Tong University-Yale University Joint Research Center for Health Policy, has been interviewed by CGTN for the 33nd time (the 53nd time by CGTN / ShanghaiTV) since the COVID-19 pandemic. On October 11, 2020, Zhao commented on China’s joining COVAX is the outset of a shared community of health for all on “China 24” of CGTN. 

Anchor: From your perspective, what does China’s participation in COVAX mean for global fight against COVID-19?

ZHAO: China’s joining Covax is really import for the coalition. First, before China’s joining, although there were more than 170 countries and regions in the coalition, no countries or regions have a COVID-19 vaccine in the 3rd clinal trial. That is to say, before China’s joining, the Covax seemed to be an utopia. It is well known that China has 4 types of COVID-19 vaccines in the third clinical trial. China’s joining makes the existence of Covax become meaningful. Second, for combating COVID-19 in the world, China’s joining Covax largely means the outset of global fight against COVID-19, due to the fact that up to now, all prior members of Covax had no ability to develop the vaccine. Further, because the pandemic in China has been under control for about half a year and China has 4 types of COVID-19 vaccines from the total 9 in the world, China’s joining is to help the world, especially the developing countries to commonly fight against the pandemic of COVID-19. 

Anchor: China has pledged to make its vaccines a global public good, ensuring that developing countries have equal access. How important will that be, given battles we can expect to see internationally. 

ZHAO: The most importance of the China’s commitment that makes COVID-19 vaccines into a global good is the outset of the implementation of the concept of a shared community of health for all. There are only 4 countries whose COVID-19 vaccines are in the third clinical trial. Except for China, the other 3 countries are US, UK, and Russia. For the most majority of developing countries, it is very difficult for them to have the ability to develop the vaccine. If the three countries whose covida-19 vaccines are in the third clinical trial, make the same commitment that turn covid-19 vaccine into a global good, it is not only favorable to ending the pandemic of COVID-19 in the world as soon as possible, but also helpful to reach a consensus that the world needs to build a common prevention and control mechanism for the future global pandemic. Only through this, human beings may have the chance to escape another new pandemic. 

Contributor: SIPA, SJTU

Data: October 12, 2020


沪交ICP备20200053
Copyright © 2020上海交大—耶鲁大学卫生政策联合研究中心/SJTU-Yale Joint Center for Health Policy